Table 2.
Hepatic involvement in obese study group at baseline in comparison to healthy controls or laboratory reference range.
| Obese cohort median (range) |
Healthy controls median (range) |
P | |
|---|---|---|---|
| ALT (ULN 39 U/L) | 19 U/L (10–60) | ||
|
| |||
| AST (ULN 41 U/L) | 23 U/L (10–41) | ||
|
| |||
| GGT (UNL 44 U/L) | 22 U/L (3–44) | ||
|
| |||
| Bilirubin (ULN 9 μmol/L) | 5 μmol/L (2–14) | ||
|
| |||
| Transient elastography (ULN 6.5 kPa) | 5.9 kPa (3.40–8.30) n = 28 Above ULN: n = 8 (28%) |
4.45 kPa (2.45–8.85) n = 270 |
<0.01 |
| Enhanced liver fibrosis (ELF) test cut-off for “any” fibrosis: 9.28 |
9.0 (7.87–9.60) n = 33 Above 9.28: n = 7 (21%) |
8.6 (7.33–11.52) N = 85 |
0.033 |
ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutaryl transpeptidase; ULN: upper limit of normal; TE: transient elastography; ELF: enhanced liver fibrosis panel.